Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

767 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.
Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U. Baumann KH, et al. Among authors: sehouli j. Ann Oncol. 2012 Sep;23(9):2265-2271. doi: 10.1093/annonc/mds003. Epub 2012 Feb 29. Ann Oncol. 2012. PMID: 22377563 Free article. Clinical Trial.
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Among authors: sehouli j. Oncogene. 2005 Feb 3;24(6):1053-65. doi: 10.1038/sj.onc.1208298. Oncogene. 2005. PMID: 15558012
[Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO].
Schmalfeldt B, du Bois A, Burges A, Emons G, Fink D, Gropp M, Hasenburg A, Jäger W, Kimmig R, Kiechle M, Kommoss F, Kreienberg R, Kuhn W, Lück HJ, Meier W, Münstedt K, Ortmann O, Pfisterer J, Richter B, Runnebaum I, Schröder W, Sehouli J, Tanner B, Wagner U, Weis J. Schmalfeldt B, et al. Among authors: sehouli j. Zentralbl Gynakol. 2006 Feb;128(1):11-7. doi: 10.1055/s-2006-921345. Zentralbl Gynakol. 2006. PMID: 16450281 German.
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
Sehouli J, Oskay-Ozcelik G, Kühne J, Stengel D, Hindenburg HJ, Klare P, Heinrich G, Schmalfeldt B, Mertens H, Camara O, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Sehouli J, et al. Ann Oncol. 2006 Jun;17(6):957-61. doi: 10.1093/annonc/mdl079. Epub 2006 Apr 6. Ann Oncol. 2006. PMID: 16600975 Free article. Clinical Trial.
ErbB-3 predicts survival in ovarian cancer.
Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG. Tanner B, et al. Among authors: sehouli j. J Clin Oncol. 2006 Sep 10;24(26):4317-23. doi: 10.1200/JCO.2005.04.8397. Epub 2006 Aug 8. J Clin Oncol. 2006. PMID: 16896008
767 results